Mental Health Home > Levomilnacipran

Available by prescription only, levomilnacipran is used to treat major depressive disorder. By increasing the levels of certain chemicals in the brain, the medicine is effective in improving the symptoms of clinical depression. Potential side effects include a rapid heart rate, nausea, and constipation. It comes as a capsule that is taken once daily.

What Is Levomilnacipran?

Levomilnacipran (Fetzima™) is a prescription medication approved to treat major depressive disorder, also simply referred to as clinical depression. It belongs to a class of medicines known as antidepressants.
(Click What Is Levomilnacipran Used For? for more information on this topic, including possible off-label uses.)

Are There Side Effects?

Just like any medicine, levomilnacipran can cause side effects. However, not everyone who takes the drug will experience problems. Most people tolerate it quite well.
If side effects do occur, in most cases, they are minor and either require no treatment or are treated easily by you or your healthcare provider. Serious reactions are less common.
Some of the most common side effects seen with levomilnacipran include but are not limited to:
  • Nausea
  • Constipation
  • Excessive sweating
  • Increased heart rate.
(Click Levomilnacipran Side Effects to learn more, including potentially serious side effects you should report immediately to your healthcare provider.)
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation

Topics & Medications


Related Channels

eMedTV Links
Copyright © 2006-2020 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.